NIAID Emerging and Re-emerging Infectious Diseases NIAID Bioinformatics Resource Centers NIAID Structural Genomic Centers Center for Structural Genomics of Infectious Disease
Seattle Structural Genomics Center for Infectious Disease

MymaA.01530.e: Enoyl-CoA hydratase EchA19

Target Characteristics

from organism: Mycobacterium marinum ATCC BAA-535 / M
most recent status: in PDB
center reference id: MymaA.01530.e
is community request: False
associated disease: Cutaneous ulcerations, deep abscesses
NIH risk group: 2
is select agent: False
NIH priority
pathogens category:
IIIC

Ordering Clones & Proteins

If there are materials available for this target, they will be listed below. Materials can be ordered from SSGCID using the button in the "order material" column. Clicking the button will add the material to a virtual cart. You may order multiple materials at a time at no cost to you, as this contract is funded by NIAID. When you are ready to place your order, click the "Place Order" link which will appear in the top right corner of the page after you place your first item in your cart.

Clones*

CENTER
REFERENCE ID
DOMAIN/REGION
DESCRIPTION
INFO AA
START
AA
STOP
ORDER
MATERIAL
MymaA.01530.e.A1.GE30188 Full length( MymaA.01530.e ) 1 274 GE30188
* SSGCID clones represent un-induced expression constructs which have been verified by sequencing from vector primers. Clones may contain a tag, such as N-term 6xHis. Get sequence information using the button in the "info" column.

Proteins

CENTER
REFERENCE ID
DOMAIN/REGION
DESCRIPTION
INFO AA
START
AA
STOP
ORDER
MATERIAL
MymaA.01530.e.A1.PS00838 Full length( MymaA.01530.e ) 1 274

Structures

image of structure for 4F47
4F47
Deposited: 5/10/2012
Determination: XRay
Diffraction Image
Clone: MymaA.01530.e.A1.GE30188
Protein: MymaA.01530.e.A1.PS00838

Publications by SSGCID

Increasing the structural coverage of tuberculosis drug targets.
Abendroth J, Abramov A, Armour B, Barrett LK, Baugh L, Begley DW, Buchko GW, Choi R, Clifton MC, Dieterich SH, Dranow DM, Edwards TE, Fairman JW, Ferrell M, Fox D, Gardberg AS, Hewitt SN, Lorimer D, Lyons-Abbott S, Mundt E, Muruthi MM, Myers J, Myler PJ, Napuli AJ, Phan I, Sekar A, Serbzhinskiy D, Stacy R, Staker BL, Stewart LJ, Taylor BM, Thompkins K, Tran N, Van Voorhis WC, Zhang Y
Tuberculosis (Edinb) - 2014
volume 95, issue 2, pages 142-8
PMID: 25613812; PMCID: PMC4361283
PDB: 3GVC, 3GVG, 3GWC, 3H7F, 3H81, 3HE2, 3HWI, 3HWK, 3HZG, 3ICO, 3KHP, 3LLS, 3MOY, 3MPZ, 3MYB, 3NDN, 3NDO, 3NF4, 3NG3, 3NJD, 3NWO, 3O0M, 3O38, 3OC6, 3OC7, 3OEC, 3OI9, 3OKS, 3OL3, 3OL4, 3OME, 3P0T, 3P2Y, 3P4I, 3P4T, 3P5M, 3P85, 3PE8, 3PGX, 3PK0, 3PPI, 3PXX, 3PZY, 3Q1T, 3Q8N, 3QBP, 3QDF, 3QH4, 3QHA, 3QIV, 3QK8, 3QKA, 3QLJ, 3QMJ, 3QRE, 3QUA, 3QUV, 3QXI, 3QXZ, 3QYR, 3R0O, 3R1I, 3R1J, 3R20, 3R2N, 3R4T, 3R6H, 3R6O, 3R7K, 3R8C, 3R9P, 3R9Q, 3R9R, 3R9S, 3R9T, 3RD5, 3RD7, 3RD8, 3RFQ, 3RIH, 3RR2, 3RR6, 3RRP, 3RRV, 3RSI, 3RV2, 3S55, 3S82, 3SBX, 3SF6, 3SLL, 3SVK, 3SVT, 3SWO, 3SWT, 3SWX, 3SX2, 3T3W, 3T7C, 3TAV, 3TCR, 3TDE, 3TJR, 3TL3, 3TLF, 3TRR, 3TSC, 3TX2, 3TZQ, 3TZU, 3U0A, 3U0B, 3UCX, 3UVE, 4DI1, 4DIE, 4DQ8, 4DXL, 4ED4, 4EGE, 4EGF, 4EMD, 4EO9, 4EYE, 4F3W, 4F47, 4FFC, 4GK6, 4HDT, 4HR3, 4I1Y, 4IJN, 4IV6, 4IZ9, 4J5I, 4KAM, 4LGV, 4O2D, 5EJ2

Citations by Others


This list was obtained from Google Scholar searches using the Open Source tool https://github.com/ckreibich/scholar.py and each citation has been manually reviewed.

External Resources

Resource Reference ID
OrthoMCL: OG5_169926
PATRIC ID: fig|216594.6.peg.5361
RefSeq: YP_001853261.1
UniProt: B2HI06

Enzyme & Pathway Information

Pathway Pathway ID EC Number
fatty acid beta-oxidation I FAO-PWY 4.2.1.17
L-isoleucine degradation I ILEUDEG-PWY 4.2.1.17
oleate beta-oxidation PWY0-1337 4.2.1.17
phenylacetate degradation I (aerobic) PWY0-321 4.2.1.17
benzoyl-CoA degradation I (aerobic) PWY-1361 4.2.1.17
fermentation to 2-methylbutanoate PWY-5109 4.2.1.17
fatty acid beta-oxidation II (peroxisome) PWY-5136 4.2.1.17
unsaturated, even numbered fatty acid beta-oxidation PWY-5138 4.2.1.17
superpathway of glyoxylate cycle and fatty acid degradation PWY-561 4.2.1.17
superpathway of phenylethylamine degradation PWY-6071 4.2.1.17
4-hydroxybenzoate biosynthesis III (plants) PWY-6435 4.2.1.17
fatty acid beta-oxidation VI (peroxisome) PWY66-391 4.2.1.17
pyruvate fermentation to hexanol (engineered) PWY-6863 4.2.1.17
superpathway of cholesterol degradation I (cholesterol oxidase) PWY-6928 4.2.1.17
superpathway of testosterone and androsterone degradation PWY-6937 4.2.1.17
androstenedione degradation PWY-6944 4.2.1.17
superpathway of cholesterol degradation II (cholesterol dehydrogenase) PWY-6947 4.2.1.17
methyl ketone biosynthesis (engineered) PWY-7007 4.2.1.17
4-coumarate degradation (anaerobic) PWY-7046 4.2.1.17
fatty acid salvage PWY-7094 4.2.1.17
jasmonic acid biosynthesis PWY-735 4.2.1.17
docosahexaenoate biosynthesis III (6-desaturase, mammals) PWY-7606 4.2.1.17
(8E,10E)-dodeca-8,10-dienol biosynthesis PWY-7654 4.2.1.17
Spodoptera littoralis pheromone biosynthesis PWY-7656 4.2.1.17
(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate biosynthesis (6-desaturase) PWY-7726 4.2.1.17
toluene degradation to benzoyl-CoA (anaerobic) PWY-81 4.2.1.17
L-valine degradation I VALDEG-PWY 4.2.1.17

Sequences

These sequences are the native gene sequence; sequences of constructs derived from these sequences may differ due to codon optimization or other protocols. To find the specific sequence of any material you may have ordered, click on the "more" button next to the name of that material.
AA Sequence
MAPNTSETPA NGESGPDALV EQRGHTLIVT MNRPSRRNAL SGEMMQIMVE AWDRVDNDPD IRCCILTGAG GYFCAGMDLK AATKKPPGDS FKDGSYDPSR IDALLKGRRL KKPLIAAVEG PAIAGGTEIL QGTDIRVAAE SAKFGISEAK WSLYPMGGSA VRLVRQIPYT VACDLLLTGR HITAAEAKEM GLVGHVVPDG QALTKALEIA EIIAANGPLA VQAILRTIRE TEGMHENEAF KIDTRIGIEV FLSDDAKEGP QAFAQKRKPN FQNR

NT Sequence
GTGGCCCCGA ATACTTCCGA GACGCCAGCA AACGGGGAGT CCGGACCAGA CGCGCTGGTG GAGCAGCGCG GGCACACCCT GATCGTGACG ATGAATCGCC CGTCCCGGCG TAACGCGCTT AGTGGCGAAA TGATGCAAAT CATGGTCGAG GCCTGGGATC GCGTCGACAA CGATCCCGAC ATCCGCTGCT GCATCCTGAC CGGCGCGGGC GGCTACTTCT GCGCTGGGAT GGACCTCAAG GCGGCGACCA AGAAGCCGCC GGGCGACTCA TTCAAGGACG GCAGCTACGA CCCGTCGCGC ATCGACGCGC TGCTGAAGGG CCGCAGGCTG AAAAAGCCGC TGATCGCCGC CGTCGAGGGC CCCGCGATCG CCGGCGGAAC CGAGATTCTG CAAGGTACCG ACATTCGCGT CGCCGCCGAG AGCGCCAAGT TCGGCATCTC GGAGGCCAAG TGGAGCCTGT ACCCGATGGG AGGCTCGGCG GTGCGACTGG TCCGCCAGAT CCCCTACACG GTGGCCTGCG ATCTCCTGCT GACCGGACGG CACATCACTG CCGCGGAGGC CAAGGAGATG GGGCTGGTGG GCCACGTCGT GCCCGACGGC CAGGCGCTGA CCAAGGCGCT GGAAATTGCG GAGATCATCG CGGCCAACGG GCCTCTTGCG GTCCAGGCGA TCCTGCGCAC CATCCGCGAA ACCGAGGGCA TGCACGAGAA CGAGGCGTTC AAGATCGACA CTCGGATCGG CATCGAGGTG TTCTTGTCCG ACGACGCCAA AGAAGGTCCG CAGGCGTTCG CGCAGAAGCG CAAACCCAAC TTCCAGAACC GC

© 2021 Seattle Children's Research Institute. All rights reserved.